Clinical trials: Fluid-therapy
Alzheimer Disease
Evaluating Simvastatin's Potential Role in Therapy
The purpose of this study is to see how simvastatin, a cholesterol-lowering drug, affects processes related to the development of Alzheimer's disease, including: 1) levels of a substance called beta-amyloid-42 found in the spinal…
- Trial name
- ESPRIT (NCT00486044)
- Testing
- Simvastatin
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Peripheral Arterial Hemorrhage
Treatment of Peripheral Arterial Hemorrhage With Lava LES (The LAVA Study)
To evaluate the safety and effectiveness of the Lava LES for the embolic treatment of arterial hemorrhage in the peripheral vasculature.
- Trial name
- NCT04649255
- Testing
- Liquid Embolic
- Where
- 9 sites in United States
- Volunteers
- 113 people
- Sponsor
- BlackSwan Vascular, Inc.
Acute Lymphoblastic Leukemia
A Study Comparing the Blood Levels of Both Pegaspargase (S95014) Formulations (Liquid vs Lyophilized) in the Treatment of Paediatric Patients With Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to compare the pharmacokinetics (PK) of both lyophilized and liquid S95014 formulations during the induction phase after a single IV dose in newly diagnosed paediatric patients with ALL
- Trial name
- ALL (NCT04954326)
- Testing
- Lyophilized S95014, Liquid S95014
- Where
- 6 sites in Russia
- Volunteers
- 89 people
- Sponsor
- Institut de Recherches Internationales Servier
Wounds and Injuries
Processed Amniotic Fluid (pAF) for the Treatment of Chronic Wounds
A prospective randomized controlled study to determine the safety and feasibility of using processed amniotic fluid (pAF) to expedite healing in chronic wounds.
- Trial name
- NCT04438174
- Testing
- Processed Amniotic Fluid, Standard of Care Wound Treatment Regimen
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Utah
COVID-19
Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)
The purpose of the study is to determine if Liquid Alpha1-Proteinase Inhibitor (Human) (Liquid Alpha1-PI) plus SMT can reduce the proportion of participants dying or requiring intensive care unit (ICU) admission on or before Day…
- Trial name
- NCT04547140
- Testing
- Liquid Alpha1-Proteinase Inhibitor (Human), Standard Medical Treatment
- Where
- 20 sites in United States, Brazil and 3 more
- Volunteers
- 57 people
- Sponsor
- Grifols Therapeutics LLC
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab
This is an open-label, prospective, randomized, multicenter phase II trial that will evaluate the efficacy and safety of intermittent addition of cetuximab to a FOLFIRI-based first line therapy to patients with RAS (Rat…
- Trial name
- NCT04554836
- Testing
- Cetuximab, FOLFIRI
- Where
- 4 sites in Germany
- Volunteers
- 6 people
- Sponsor
- TheraOp
Acute Upper Respiratory Infections
Clinical Trial of Efficacy and Safety of Anaferon for Children Liquid Dosage Form in the Treatment of Acute Upper Respiratory Infections
Purpose of the study: To assess efficacy of Anaferon for children liquid dosage form in the treatment of acute upper respiratory tract infections.
- Trial name
- NCT03162458
- Testing
- Anaferon for children (liquid dosage form)
- Where
- 7 sites in Russia
- Volunteers
- 142 people
- Sponsor
- Materia Medica Holding
NSCLC
Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)
The phase II APPLE trial gives the opportunity to prospectively validate liquid biopsies as a new standard for testing tumor progression compared with conventional radiological procedure in EGFR mutant advanced NSCLC patients.
- Trial name
- APPLE (NCT02856893)
- Testing
- Osimertinib, Gefitinib
- Where
- 23 sites in Belgium, France and 4 more
- Volunteers
- 156 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Septic Shock
The Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care Trial
The purpose of this trial is to assess patient important benefits and harms of IV fluid restriction vs. standard care fluid therapy in patients with septic shock.
- Trial name
- CLASSIC (NCT03668236)
- Testing
- Isotonic crystalloids
- Where
- 31 sites in Belgium, Czechia and 6 more
- Volunteers
- 1,554 people
- Sponsor
- Anders Perner, MD, PhD
Iron Deficiency Anemia, Iron-deficiency
Oral Iron Versus Oral Iron Plus a Web-based Behavioral Intervention in Young Children (IRONCHILD)
Iron deficiency anemia (IDA) affects nearly half a million young children in the United States. Most children take liquid iron medicine by mouth for at least 3 months.
- Trial name
- NCT04371536
- Testing
- Ferrous Sulfate, IRONCHILD
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Baylor College of Medicine
Non-Cardiac/ Non-Thoracic Surgery, Abdominal Surgery
Assisted Fluid Management IDE Study
The primary objective of this study is to evaluate the performance of the Acumen™ Assisted Fluid Management (AFM) Feature in its ability to predict a subject's fluid responsiveness.
- Conditions
- Non-Cardiac/ Non-Thoracic Surgery, Abdominal Surgery, Pelvic Surgery, Major Peripheral Vascular Surgery
- Trial name
- AFM (NCT03469570)
- Testing
- EV1000 Clinical Platform with Assisted Fluid Management (AFM) Feature
- Where
- 10 sites in United States
- Volunteers
- 330 people
- Sponsor
- Edwards Lifesciences
Schizophrenia
Trial of D-Cycloserine in Schizophrenia
To characterize further the effects of D-cycloserine augmentation of antipsychotic treatment on negative symptoms, performance on neurocognitive tasks, and on markers for glutamatergic, dopaminergic and serotonergic function in…
- Trial name
- NCT00000371
- Testing
- D-cycloserine
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
The aim of this study is to learn more about the following treatment options in adults with CIDP: Subcutaneous self-infusion with HyQvia. Intravenous infusion with Gammagard/Kiovig.
- Trial name
- NCT02549170
- Testing
- HYQVIA, IGIV GAMMAGARD LIQUID/KIOVIG, IGIV GAMUNEX®-C
- Where
- 83 sites in United States, Argentina and 20 more
- Volunteers
- 138 people
- Sponsor
- Baxalta now part of Shire
Constipation
A Preference Study Comparing Kristalose® and Liquid Lactulose
This study will evaluate whether patients have an overall preference for Kristalose® or liquid lactulose based on taste, consistency, and portability.
- Trial name
- NCT00712543
- Testing
- lactulose (Kristalose®), liquid lactulose
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Cumberland Pharmaceuticals
Sequelae of Perinatal Brain Injury
Efficacy and Safety Clinical Trial of Tenoten for Children Liquid Dosage Form Therapy in Infants With Sequelae of Perinatal Brain Injury
Purpose of the study: To assess the clinical efficacy of Tenoten for children liquid dosage form therapy (10 oral drops per day for 12 weeks) in Infants with Sequelae of Perinatal Brain Injury (mild-to-moderate cerebral…
- Trial name
- NCT03159611
- Testing
- Tenoten for children
- Where
- 10 sites in Russia
- Volunteers
- 182 people
- Sponsor
- Materia Medica Holding
HIV Infections
Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients
This pilot study focuses on the persistence of central nervous system (CNS) immune activation that has been observed in the presence of 'effective' combination antiretroviral therapy (cART).
- Trial name
- NCT00672932
- Testing
- raltegravir
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of California, San Francisco
Breast Cancer
Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant
The purpose of this clinical trial is to study of the molecular features of postmenopausal women with hormone receptor-positive (HR+) HER2-negative advanced breast cancer on first-line treatment with ribociclib and letrozole and…
- Trial name
- BioItaLEE (NCT03439046)
- Testing
- Ribociclib, Letrozole, Alpelisib
- Where
- 41 sites in Italy
- Volunteers
- 287 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular (Wet) Age-related Macular Degeneration
A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment
Researchers are looking for a better way to treat people who have neovascular (wet) age-related macular degeneration (nAMD or wet AMD).
- Trial name
- XPAND (NCT05473715)
- Testing
- Aflibercept(BAY86-5321, Eylea)
- Where
- 3 sites in Canada, United Kingdom
- Volunteers
- 3 people
- Sponsor
- Bayer
Major Abdominal Surgery
REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery
Physicians differ in their approaches to surgical fluid therapy, with some preferring higher volumes and others lower volumes. Each approach has potential advantages and disadvantages.
- Trial name
- NCT02073162
- Testing
- Major Abdominal Surgery
- Where
- United States
- Volunteers
- 3,000 people
- Sponsor
- The Cleveland Clinic
Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD
Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)
To evaluate and compare two individualised ranibizumab treatment regimens, differentiated by the definition of disease activity, which determines the treatment interval until the next injection.
- Trial name
- FLUID (NCT01972789)
- Testing
- Ranibizumab
- Where
- 16 sites in Australia
- Volunteers
- 349 people
- Sponsor
- Novartis Pharmaceuticals